Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

por Arteaga, Carlos L
Publicado 2003

ERBB receptors in cancer: signaling from the inside

por Arteaga, Carlos L
Publicado 2011

Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β

por Dumont, Nancy, Arteaga, Carlos L
Publicado 2000

Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response

por Rexer, Brent N, Arteaga, Carlos L
Publicado 2014

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

por Garrett, Joan T., Chakrabarty, Anindita, Arteaga, Carlos L.
Publicado 2011

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

por Garrett, Joan T., Chakrabarty, Anindita, Arteaga, Carlos L.
Publicado 2018

Mouse models and anti-HER2 therapies

por Hanker, Ariella B., Cook, Rebecca S., Arteaga, Carlos L.
Publicado 2013

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers

por Young, Christian D., Arteaga, Carlos L., Cook, Rebecca S.
Publicado 2015

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer

por Fox, Emily M., Arteaga, Carlos L., Miller, Todd W.
Publicado 2012

The genomic map of breast cancer: which roads lead to better targeted therapies?

por Balko, Justin M, Stricker, Thomas P, Arteaga, Carlos L
Publicado 2013

Heart Failure and Breast Cancer Therapies: Moving Towards Personalized Risk Assessment

por Francis, Sanjeev A., Cheng, Susan, Arteaga, Carlos L., Moslehi, Javid
Publicado 2014

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor

por Hinow, Peter, Wang, Shizhen Emily, Arteaga, Carlos L, Webb, Glenn F
Publicado 2007

Evaluation of biological agents targeted at early-stage disease

por Guix, Marta, Mayer, Ingrid A, Meszoely, Ingrid M, Arteaga, Carlos L
Publicado 2008

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

por Miller, Todd W, Rexer, Brent N, Garrett, Joan T, Arteaga, Carlos L
Publicado 2011

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

por Rexer, Brent N, Chanthaphaychith, Siprachanh, Dahlman, Kimberly Brown, Arteaga, Carlos L
Publicado 2014

Optical imaging of metabolism in HER2 overexpressing breast cancer cells

por Walsh, Alex, Cook, Rebecca S., Rexer, Brent, Arteaga, Carlos L., Skala, Melissa C.
Publicado 2011

Transforming growth factor-β induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein

por Brown, Kimberly A, Roberts, Richard L, Arteaga, Carlos L, Law, Brian K
Publicado 2004

TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association

por Zonneville, Justin, Safina, Alfiya, Truskinovsky, Alexander M., Arteaga, Carlos L., Bakin, Andrei V.
Publicado 2018

Drug response in organoids generated from frozen primary tumor tissues

por Walsh, Alex J., Cook, Rebecca S., Sanders, Melinda E., Arteaga, Carlos L., Skala, Melissa C.
Publicado 2016

Author Correction: Drug response in organoids generated from frozen primary tumor tissues

por Walsh, Alex J., Cook, Rebecca S., Sanders, Melinda E., Arteaga, Carlos L., Skala, Melissa C.
Publicado 2019